Improved Pharma initiates research and development program

Addition of staff and new instrumentation in support of solid lipid nanoparticle research

Improved Pharma is investing in an internal R&D program focused on solid lipid nanoparticles (SLNs). A recent expansion of their research facility included resources dedicated to this endeavor.

WEST LAFAYETTE, Ind., July 1, 2025 /PRNewswire/ -- SLNs are a type of nanocarrier used in drug delivery and vaccine development. They are composed of stabilized lipids and can encapsulate active pharmaceutical ingredients (APIs). This formulation approach can enable the transport of active molecules directly to target cells, protect encapsulated molecules from degradation, and enhance the solubility and bioavailability of poorly soluble drugs. The most well-known SLN formulations include the Moderna and Pfizer COVID-19 vaccines. However, there is little consensus on the structure of SLNs with published depictions varying greatly. Understanding the structure is crucial for improving the stability, efficacy, and reproducibility of SLN formulations.

To support this new endeavor, Improved Pharma is pleased to add Lauren Smith to the team of expert scientists. Ms. Smith recently graduated from Indiana University with a B.S. in Chemistry and a minor in Criminal Justice. Her prior research experience includes an appointment in the Byrn Research Group at Purdue University to optimize the production of SLNs for the purpose of drug delivery. Most recently, she was a member of the Bloch Research Group at Indiana University, focused on the synthesis of metal organic frameworks, particularly by use of inductive heating.

Dr. Stephen Byrn, CSO of Improved Pharma remarked about the importance of this research. "Lauren's prior research experience with SLNs is critical for our success. As the industry moves forward with nanoparticle-based individualized personal medicine and nanoparticle encapsulated drugs, our knowledge, facilities, equipment, and problem-solving abilities will become more important for advancing these therapies and addressing patient needs, especially in the cancer area."

To assist with the physical evaluation of the SLNs, Improved Pharma recently acquired a Malvern Zetasizer Ultra Red Label instrument for the measurement of particle and molecular size, and particle charge. The instrument also includes Multi-Angle Dynamic Light Scattering (MADLS) for high-resolution sizing and particle concentration capabilities.  

About Improved Pharma
Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes. Services include solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting for the development and defense of intellectual property matters. The company was founded in 2006 by Stephen and Sarah Byrn, who also founded SSCI.

For more information about Improved Pharma's services, please contact us at 1-765-463-9951 or info@improvedpharma.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/improved-pharma-initiates-research-and-development-program-302495687.html

SOURCE Improved Pharma